Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
FASEB J ; 23(9): 2978-85, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19376816

ABSTRACT

The purpose of this study was to assess whether an alternative treatment approach that targets angiogenesis, delivered through ligand-targeted nanotherapy, would ameliorate inflammatory arthritis. Arthritis was induced using the K/BxN mouse model of inflammatory arthritis. After arthritis was clearly established, mice received three consecutive daily doses of alpha(v)beta(3)-targeted fumagillin nanoparticles. Control groups received no treatment or alpha(v)beta(3)-targeted nanoparticles without drugs. Disease score and paw thickness were measured daily. Mice that received alpha(v)beta(3)-targeted fumagillin nanoparticles showed a significantly lower disease activity score (mean score of 1.4+/-0.4; P<0.001) and change in ankle thickness (mean increase of 0.17+/-0.05 mm; P<0.001) 7 d after arthritis induction, whereas the group that received alpha(v)beta(3)-targeted nanoparticles without drugs exhibited a mean arthritic score of 9.0 +/- 0.3 and mean change in ankle thickness of 1.01 +/- 0.09 mm. Meanwhile, the group that received no treatment showed a mean arthritic score of 9.8 +/- 0.5 and mean change in ankle thickness of 1.05 +/- 0.10 mm. Synovial tissues from animals treated with targeted fumagillin nanoparticles also showed significant decrease in inflammation and angiogenesis and preserved proteoglycan integrity. Ligand-targeted nanotherapy to deliver antiangiogenic agents may represent an effective way to treat inflammatory arthritis.


Subject(s)
Arthritis, Experimental/drug therapy , Cyclohexanes/therapeutic use , Fatty Acids, Unsaturated/therapeutic use , Integrin alphaVbeta3/drug effects , Animals , Arthritis, Experimental/pathology , Cyclohexanes/pharmacology , Drug Delivery Systems/methods , Fatty Acids, Unsaturated/pharmacology , Inflammation/drug therapy , Mice , Nanoparticles/therapeutic use , Neovascularization, Pathologic/drug therapy , Sesquiterpenes/pharmacology , Sesquiterpenes/therapeutic use , Treatment Outcome
2.
J Immunol ; 180(5): 3535-42, 2008 Mar 01.
Article in English | MEDLINE | ID: mdl-18292580

ABSTRACT

The role of innate immunity in the pathogenesis of asthma is unclear. Although increased presence of neutrophils is associated with persistent asthma and asthma exacerbations, how neutrophils participate in the pathogenesis of asthma remains controversial. In this study, we show that the absence of dipeptidyl peptidase I (DPPI), a lysosomal cysteine protease found in neutrophils, dampens the acute inflammatory response and the subsequent mucous cell metaplasia that accompanies the asthma phenotype induced by Sendai virus infection. This attenuated phenotype is accompanied by a significant decrease in the accumulation of neutrophils and the local production of CXCL2, TNF, IL-1beta, and IL-6 in the lung of infected DPPI-/- mice. Adoptive transfer of DPPI-sufficient neutrophils into DPPI-/- mice restored the levels of CXCL2 and enhanced cytokine production on day 4 postinfection and subsequent mucous cell metaplasia on day 21 postinfection. These results indicate that DPPI and neutrophils play a critical role in Sendai virus-induced asthma phenotype as a result of a DPPI-dependent neutrophil recruitment and cytokine response.


Subject(s)
Cathepsin C/physiology , Neutrophil Infiltration/immunology , Neutrophils/immunology , Neutrophils/pathology , Respirovirus Infections/immunology , Respirovirus Infections/pathology , Sendai virus/immunology , Animals , Asthma/enzymology , Asthma/immunology , Asthma/pathology , Cathepsin C/deficiency , Cathepsin C/genetics , Inflammation/enzymology , Inflammation/immunology , Inflammation/virology , Male , Metaplasia/enzymology , Metaplasia/immunology , Metaplasia/pathology , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Neutrophils/enzymology , Respiratory Mucosa/enzymology , Respiratory Mucosa/immunology , Respiratory Mucosa/pathology , Respirovirus Infections/enzymology , T-Lymphocytes, Cytotoxic/enzymology , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...